Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)

Author:

Wirth Lori J.1ORCID,Tahara Makoto2,Robinson Bruce3,Francis Sanjeev4,Brose Marcia S.5,Habra Mouhammed Amir6,Newbold Kate7,Kiyota Naomi8,Dutcus Corina E.9,Mathias Elton9,Guo Matthew9,Sherman Steven I.6,Schlumberger Martin10

Affiliation:

1. Department of Medicine; Massachusetts General Hospital; Boston Massachusetts

2. Department of Head and Neck Medical Oncology; National Cancer Center Hospital East; Kashiwa Japan

3. Kolling Institute of Medical Research; University of Sydney; New South Wales Australia

4. Cardiovascular Division, Department of Medicine; Massachusetts General Hospital; Boston Massachusetts

5. Department of Otorhinolaryngology-Head and Neck Surgery, Abramson Cancer Center; University of Pennsylvania; Philadelphia Pennsylvania

6. Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

7. Thyroid and Radioactive Isotope Therapy Unit; Royal Marsden National Health Service Trust; London United Kingdom

8. Department of Medical Oncology and Hematology; Kobe University Hospital; Kobe Japan

9. Eisai, Inc; Woodcliff Lake New Jersey

10. Department of Nuclear Medicine and Endocrine Oncology; Gustave Roussy and University Paris-Saclay; Villejuif France

Funder

Eisai

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3